Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Anne Knisely(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Siqing Fu(The University of Texas MD Anderson Cancer Center), Juhee Song(The University of Texas MD Anderson Cancer Center), Anas Alshawa(The University of Texas MD Anderson Cancer Center), Jibran Ahmed(National Institutes of Health), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Abdulrazzak Zarifa(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Bettzy Stephen(The University of Texas MD Anderson Cancer Center), Yali Yang(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center)
Cancer
October 21, 2023
Cited by 17


Related Papers